Logo image of BIG1.DE

BIO-GATE AG (BIG1.DE) Stock Fundamental Analysis

FRA:BIG1 - Deutsche Boerse Ag - DE000BGAG981 - Common Stock - Currency: EUR

0.64  -0.09 (-12.33%)

Fundamental Rating

3

Taking everything into account, BIG1 scores 3 out of 10 in our fundamental rating. BIG1 was compared to 61 industry peers in the Chemicals industry. While BIG1 seems to be doing ok healthwise, there are quite some concerns on its profitability. BIG1 is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIG1 has reported negative net income.
In the past year BIG1 has reported a negative cash flow from operations.
In the past 5 years BIG1 always reported negative net income.
BIG1 had a negative operating cash flow in each of the past 5 years.
BIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFBIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

Looking at the Return On Assets, with a value of -45.48%, BIG1 is doing worse than 86.89% of the companies in the same industry.
BIG1's Return On Equity of -87.45% is on the low side compared to the rest of the industry. BIG1 is outperformed by 83.61% of its industry peers.
Industry RankSector Rank
ROA -45.48%
ROE -87.45%
ROIC N/A
ROA(3y)-23.44%
ROA(5y)-25.52%
ROE(3y)-35.49%
ROE(5y)-44.03%
ROIC(3y)N/A
ROIC(5y)N/A
BIG1.DE Yearly ROA, ROE, ROICBIG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 51.10%, BIG1 is in the better half of the industry, outperforming 78.69% of the companies in the same industry.
BIG1's Gross Margin has declined in the last couple of years.
BIG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.92%
BIG1.DE Yearly Profit, Operating, Gross MarginsBIG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

BIG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIG1 has been increased compared to 1 year ago.
The number of shares outstanding for BIG1 has been increased compared to 5 years ago.
BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIG1.DE Yearly Shares OutstandingBIG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BIG1.DE Yearly Total Debt VS Total AssetsBIG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

BIG1 has an Altman-Z score of -1.55. This is a bad value and indicates that BIG1 is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.55, BIG1 is not doing good in the industry: 85.25% of the companies in the same industry are doing better.
BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.55
ROIC/WACCN/A
WACC7.39%
BIG1.DE Yearly LT Debt VS Equity VS FCFBIG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 2.53 indicates that BIG1 has no problem at all paying its short term obligations.
BIG1 has a Current ratio of 2.53. This is in the better half of the industry: BIG1 outperforms 73.77% of its industry peers.
BIG1 has a Quick Ratio of 1.12. This is a normal value and indicates that BIG1 is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BIG1 (1.12) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.12
BIG1.DE Yearly Current Assets VS Current LiabilitesBIG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BIG1 have decreased strongly by -33.87% in the last year.
Looking at the last year, BIG1 shows a quite strong growth in Revenue. The Revenue has grown by 14.27% in the last year.
Measured over the past years, BIG1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.45% on average per year.
EPS 1Y (TTM)-33.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40.55%
Revenue 1Y (TTM)14.27%
Revenue growth 3Y12.18%
Revenue growth 5Y14.45%
Sales Q2Q%9.42%

3.2 Future

BIG1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.36% yearly.
The Revenue is expected to grow by 13.70% on average over the next years. This is quite good.
EPS Next Y-37.5%
EPS Next 2Y0%
EPS Next 3Y13.4%
EPS Next 5Y16.36%
Revenue Next Year4.65%
Revenue Next 2Y6.23%
Revenue Next 3Y10.33%
Revenue Next 5Y13.7%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BIG1.DE Yearly Revenue VS EstimatesBIG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
BIG1.DE Yearly EPS VS EstimatesBIG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BIG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIG1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIG1.DE Price Earnings VS Forward Price EarningsBIG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIG1.DE Per share dataBIG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as BIG1's earnings are expected to grow with 13.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y13.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIG1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO-GATE AG

FRA:BIG1 (5/8/2025, 7:00:00 PM)

0.64

-0.09 (-12.33%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-02 2025-05-02/amc
Earnings (Next)09-08 2025-09-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.8%
Ins Owner ChangeN/A
Market Cap5.91M
Analysts82.5
Price Target3.37 (426.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF N/A
P/OCF N/A
P/B 2.58
P/tB 5
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0.82
BVpS0.25
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.48%
ROE -87.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.1%
FCFM N/A
ROA(3y)-23.44%
ROA(5y)-25.52%
ROE(3y)-35.49%
ROE(5y)-44.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.92%
F-Score3
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.47%
Cap/Sales 2.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.53
Quick Ratio 1.12
Altman-Z -1.55
F-Score3
WACC7.39%
ROIC/WACCN/A
Cap/Depr(3y)173.09%
Cap/Depr(5y)125.88%
Cap/Sales(3y)6.02%
Cap/Sales(5y)5.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40.55%
EPS Next Y-37.5%
EPS Next 2Y0%
EPS Next 3Y13.4%
EPS Next 5Y16.36%
Revenue 1Y (TTM)14.27%
Revenue growth 3Y12.18%
Revenue growth 5Y14.45%
Sales Q2Q%9.42%
Revenue Next Year4.65%
Revenue Next 2Y6.23%
Revenue Next 3Y10.33%
Revenue Next 5Y13.7%
EBIT growth 1Y-39.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-885.71%
EBIT Next 3Y-54.47%
EBIT Next 5Y73.62%
FCF growth 1Y9.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.95%
OCF growth 3YN/A
OCF growth 5YN/A